MYELOPROLIFERATIVE NEOPLASM(MPN)-ASSOCIATED MYELOFIBROSIS
Clinical trials for MYELOPROLIFERATIVE NEOPLASM(MPN)-ASSOCIATED MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE NEOPLASM(MPN)-ASSOCIATED MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE NEOPLASM(MPN)-ASSOCIATED MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood disorder drug luspatercept under Long-Term safety review
Disease control Recruiting nowThis study looks at the long-term safety of luspatercept in people with certain blood disorders (MDS, beta-thalassemia, or myelofibrosis) who were already in a luspatercept trial. Participants either continue treatment or enter long-term follow-up to monitor side effects, disease…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM(MPN)-ASSOCIATED MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 09:35 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…
Matched conditions: MYELOPROLIFERATIVE NEOPLASM(MPN)-ASSOCIATED MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 26, 2026 09:58 UTC